Virchow Medical

Name

Virchow Medical

Legal name

Virchow Medical, Inc.

Website

https://virchowmed.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Biopsy Specimen Stewardship Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)

akta.pro primary industry

Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)

Keywords

• Biopsy catchment devices
• Liquid specimen biorepository
• Precision oncology diagnostics
• Biopsy specimen stewardship
• Molecular pathology devices

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Hospital Subscription / Device Supply: Virchow Medical provides hospital subscribers with a monthly supply of Crow's Nest Biopsy Catchment System units. Hospitals pay for the monthly supply of devices and the accessioning and storage service in the Virchow Vault biorepository. This is a recurring subscription model for medical devices and associated specimen management services.
2. Virchow Vault Biorepository Storage and Access: The company stores Liquid Companion Specimens for its hospital customers in the Virchow Vault. Oncologists at subscriber hospitals log on to virchowvault.com to order genomic sequencing or molecular testing, which routes material to a third-party CLIA-certified lab. The biorepository stores specimens for at least 18 months, providing an ongoing service relationship with hospital subscribers.
3. Molecular Testing Ordering Platform: Virchow provides an online platform (virchowvault.com) through which oncologists can order genomic sequencing and other molecular tests on stored Liquid Companion Specimens. The relevant material is routed to third-party CLIA-certified labs (e.g., Genomic Testing Cooperative, Pangea Laboratory) for execution, with Virchow facilitating the logistics and specimen access.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Virchow Medical manufactures and supplies the Crow's Nest Biopsy Catchment System, a Class I exempt disposable mechanical device used after core needle biopsies to capture dislodged tumor cells from the needle and generate a Liquid Companion Specimen. The company also operates the Virchow Vault, the world's first liquid specimen biorepository, where these specimens are stored at a CAP-accredited facility and made available to oncologists for on-demand genomic sequencing and molecular testing through the virchowvault.com portal.

Product overview

Virchow Medical offers a three-product hardware portfolio (one commercialized, two in development) plus a biorepository service. The Crow's Nest Biopsy Catchment System (commercialized, Class I exempt device) is used after core needle biopsies to capture dislodged tumor cells from the biopsy needle, generating Liquid Companion Specimens. The Cell Wrangler Fine Needle Aspirate Conserver (in development) serves the same purpose for fine needle aspirate procedures, and the MOOS Multi-Omic Octagonal Scavenger (in development) targets solid tissue excisions. All three devices feed into the Virchow Vault Liquid Specimen Biorepository (operational), which stores specimens at a CAP-accredited facility and makes them available to oncologists via virchowvault.com for on-demand genomic sequencing, NGS, and multi-omic testing.

Differentiator

Problem solved

Functional benefit

Brands

• Crow's Nest: Crow's Nest Biopsy Catchment System - A mechanical device that captures dislodged tumor cells from biopsy needles to create liquid companion specimens for molecular testing.
• Virchow Vault
• Cell Wrangler
• MOOS

Products and services

• Crow's Nest Biopsy Catchment System

Quantifiable outcome

• DNA recovered from Crow's Nest specimens is 15–18 kilobase-pairs, compared to typically <500 base-pairs from FFPE specimens — 30–36x larger
• +6 more outcomes

Named customers4 records

Segments7 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Project Santa Fe Foundation / Diagnostic Medicine ConsortiumcoreStrategic or Co-development Partner · 17 February 2026The Diagnostic Medicine Consortium (DMC) of the Project Santa Fe Foundation and Virchow Medical formed a first-of-its-kind partnership to transform laboratory insights into proactive clinical analytics for oncology patients. The collaboration integrates Virchow into the PSFF-led Clinical Lab 2.0 movement. The partnership covers four areas: de-identified data augmentation, AI algorithm development, regulatory collaboration, and educational programs. Virchow joins the Clinical Lab 2.0 movement and the Diagnostic Medicine Consortium alongside the Association for Pathology Informatics.
• PreciseMDXcoreTechnology or Integration · 2 December 2025PreciseMDX partnered with Virchow to deliver a web portal for the Virchow Vault Liquid Specimen Biobank. The user interface was designed for clinical oncologists as well as the targeted therapy research community, enabling easy ordering of molecular tests on stored Liquid Companion Specimens.
• Association for Pathology InformaticsminorStrategic or Co-development PartnerCo-founded the Diagnostic Medicine Consortium alongside the Project Santa Fe Foundation. The DMC operationalizes Clinical Lab 2.0 strategies in the real-world healthcare environment.
• Genomic Testing Cooperative (GTC)coreTechnology or IntegrationGenomic Testing Cooperative, a third-party clinical genomic testing lab in Lake Forest, California serving over 500 U.S. hospitals, accepts 5 mL liquid specimens generated by Crow's Nest users. This enables molecular testing on high-quality Liquid Companion Specimens through GTC's established lab infrastructure.
• Pangea LaboratorycoreTechnology or IntegrationPangea Laboratory, a third-party clinical genomic testing lab in Tustin, California, accepts 5 mL liquid specimens generated by Crow's Nest users alongside Genomic Testing Cooperative, providing molecular testing services for Liquid Companion Specimens.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Exact Sciences: Exact Sciences develops non-invasive cancer diagnostics including Cologuard and Oncotype products. Comparable to Virchow because both sell into hospital and clinical workflows for cancer molecular testing and precision oncology decision-making.
• Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based cancer diagnostics. Comparable to Virchow because both focus on capturing and analyzing tumor-derived material from minimally invasive procedures for oncology molecular testing.
• NeoGenomics: NeoGenomics provides oncology-focused clinical laboratory services including molecular testing and pathology. Comparable to Virchow because both serve hospital oncology customers with specimen-based molecular diagnostic workflows, and Virchow Vault specimens ultimately route to similar reference labs.
• Natera: Natera specializes in cell-free DNA and molecular diagnostics, including oncology applications. Comparable to Virchow because both leverage liquid/specimen-based approaches to enable precision medicine and molecular profiling without requiring additional patient procedures.
• ANGLE plc: ANGLE plc has developed the Parsortix system for capturing circulating tumor cells from blood samples. Comparable to Virchow because both are developing proprietary specimen capture technologies that enable liquid biopsy and downstream molecular analysis.

Broad incumbents

• Becton Dickinson (BD): BD is a major medical device manufacturer with biopsy and specimen management product lines. Comparable to Virchow because both supply hospitals with biopsy-related devices and consumables; BD is the type of large incumbent that could enter the biopsy catchment category over time.
• Foundation Medicine: Foundation Medicine, a Roche subsidiary, provides comprehensive genomic profiling of solid tumors. Comparable to Virchow because both enable molecular testing on tumor specimens to inform targeted therapy selection, though Foundation operates at vastly larger scale.
• Bio-Techne: Bio-Techne is a life sciences tools and diagnostics company offering reagents and instruments for molecular and cellular analysis. Comparable to Virchow because both serve the molecular diagnostics workflow with tools that improve specimen quality for downstream analysis.

Emerging players

• Tempus Labs: Tempus is a precision medicine company combining molecular profiling with AI/data analytics. Comparable to Virchow because both leverage multi-omic specimen assets and AI algorithm development to serve oncologists and pharma/biotech customers.
• Caris Life Sciences: Caris provides molecular profiling services and is developing AI-driven precision medicine tools. Comparable to Virchow because both are building specimen-plus-data businesses in oncology with an emphasis on AI-augmented diagnostics and biopharma R&D partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/virchowmed

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virchow Medical